Identifies KLF5's role in inducing gene expression changes in metastatic pancreatic cancer, suggesting a potential therapeutic target.
Pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of cancer mortality in the U.S., where more than 80% of the cases are diagnosed with metastatic PDAC (mPDAC). In this study, Maeda et al. utilized a CRISPR screen in human patient-derived xenografts from primary and lung metastatic tumors and identified the transcription factor KLF5 as an upstream modulator regulating the mPDAC phenotype. Using a combination of biochemical and molecular experiments together with single-cell genome-wide assays, the authors discovered that KLF5 induces epigenetic modifiers including NCAPD2 and MTHFD1, which in turn regulate the expression of a distinct gene profiles controlling the biology of mPDAC. Altogether, the authors defined a cascade of events acting as a domino effect triggered by KLF5, modifying the epigenetic landscape in mPDAC to support metastatic growth.
No takes yet. Share an insight, caveat, or question.
Ruiz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: